FENC Overview

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

Wall Street analysts forecast FENC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FENC is14.67 USD with a low forecast of 13.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Fennec Pharmaceuticals Inc revenue for the last quarter amounts to 13.78M USD, increased 73.84

Fennec Pharmaceuticals Inc. EPS for the last quarter amounts to -0.15 USD, increased 114.29

Fennec Pharmaceuticals Inc (FENC) has 29 emplpoyees as of April 21 2026.

Today FENC has the market capitalization of 234.09M USD.